TriLink BioTechnologies® Announces Manufacturing Capabilities Expansion as mRNA Manufacturing Facility Nears Completion
May 24 2023 - 8:10AM
Business Wire
GMP Facility Expected to Simplify the mRNA Drug
Substance Development Process; Slated to Welcome Customers in Early
2024
TriLink BioTechnologies
(TriLink®), a Maravai LifeSciences company (NASDAQ: MRVI)
and global provider of life science reagents and services, has
announced the expansion of its mRNA manufacturing capabilities to
serve late-phase drug developers. TriLink’s construction of the new
32,000-square-foot, cGMP-grade facility solidifies its commitment
to advancing the field as more mRNA-based therapeutics and vaccines
enter later-stage clinical trials.
TriLink has reliably delivered GMP services to its customers
since the debut of its first cGMP manufacturing facility in 2015.
Built to meet the need of a rapidly growing market, the new cGMP
facility is expected to contribute to the development of vital mRNA
therapeutics. The building has been designed for the cGMP
manufacture of mRNA-based in vivo gene editing, gene-edited cell
therapies, protein replacement therapies, cancer vaccines, and
infectious disease vaccines.
“The expansion of our cGMP mRNA manufacturing capabilities marks
a major milestone for TriLink and our partners,” said Becky Buzzeo,
Chief Commercial Officer at Maravai LifeSciences. “Drug developers
will soon be able to leverage our team’s 25-plus years of industry
expertise, helping to take critical therapeutics from concept to
plasmid DNA through to late-phase clinical mRNA drug substance
manufacturing with ease.”
Just minutes from the company’s San Diego headquarters, the new
facility boasts ISO 7 cleanrooms and increased mRNA capacity (1g to
>50g per batch), with comprehensive in-house analytical services
also available. “Our team took great care in building and designing
our new facility– it’s truly been a labor of love,” added Rob
Carpenter, Vice President of Engineering at TriLink. “In addition
to having access to a state-of-the-art facility, developers will
also have a direct line to our experienced team to help with
process optimization, scale-up, validation, and qualification
capabilities.”
To learn more about TriLink’s products and services, visit
trilinkbiotech.com
About TriLink BioTechnologies
TriLink BioTechnologies, a Maravai LifeSciences company, is
helping to realize the power and potential of mRNA. As a global
leader in nucleic acid and mRNA solutions for more than 25 years,
TriLink delivers unrivaled chemical and biological experience, CDMO
services, and high-quality readymade and custom materials,
including its proprietary CleanCap® mRNA capping technology.
Pharmaceutical leaders, biotech disruptors and world governments
depend on TriLink to meet their greatest challenges, from
delivering the COVID-19 vaccine at warp speed, to empowering
innovative treatments in oncology, infectious diseases, cardiology,
and neurological disorders, to enabling future pandemic response
plans.
For more information about TriLink, visit
www.trilinkbiotech.com.
About Maravai
Maravai is a leading life sciences company providing critical
products to enable the development of drug therapies, diagnostics,
and novel vaccines. Maravai’s companies are leaders in providing
products and services in the fields of nucleic acid synthesis and
biologics safety testing to many of the world’s leading
biopharmaceutical, vaccine, diagnostics, and cell and gene therapy
companies.
For more information about Maravai LifeSciences, visit
www.maravai.com.
Forward-looking Statements
This press release may contain “forward-looking statements”
within the meaning of the safe harbor provisions of the U.S.
Private Securities Litigation Reform Act of 1995. Investors are
cautioned that statements in this press release which are not
strictly historical statements constitute forward-looking
statements, including, without limitation, statements related to
the expectation that our expanded manufacturing capabilities will
simplify and contribute to mRNA therapeutics development, our
ability to attract and serve late-phase drug developers, an
increase of mRNA-based therapeutics and vaccines entering
later-stage clinical trials, and our ability to help to take
critical therapeutics from concept through late-phase clinical mRNA
drug substance manufacturing constitute forward-looking statements
identified by words like “expect,” “estimate,” “may,” “soon,”
“nears,” “slated,” “anticipate,” or “could” and similar
expressions. Such forward-looking statements are subject to a
number of risks and uncertainties that could cause actual results
to differ materially from those anticipated, including, without
limitation and uncertainties related to construction and permitting
delays, availability and delays in delivery of equipment, continued
validation of the safety and effectiveness of our technology, and
new scientific developments and competition from other products.
These and other risks and uncertainties are described in greater
detail in the “Risk Factors” section of our most recent Annual
Report on Form 10-K, as well as other reports on file with the U.S.
Securities and Exchange Commission. Actual results may differ
materially from those contemplated by these forward-looking
statements, and therefore you should not rely upon them. These
forward-looking statements reflect our current views and we do not
undertake to update any of these forward-looking statements to
reflect a change in its views or events or circumstances that occur
after the date hereof except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230524005159/en/
Liz Robinson, PR Account Supervisor at CG Life,
lrobinson@cglife.com, 847-702-8099
Maravai LifeSciences (NASDAQ:MRVI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Maravai LifeSciences (NASDAQ:MRVI)
Historical Stock Chart
From Sep 2023 to Sep 2024